OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.80
0.00 (0.00%)
▲
5d:
+2.56%
30d:
+1.45%
90d:
+86.67%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
OVID is down 4.8% this week, but smart money is accumulating calls. Top strike: $1.5 2026-07-17 with 25 OI. Call ratio: 100% View Scanner →
Strength: 7.4/10
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called OVID this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OVID shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OVID shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.80, which is considered fair relative to its 30-day fair value range of $2.63 to $2.89.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.67, while resistance sits at $2.99.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.25 (+87.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.67, while resistance sits at $2.99.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.25 (+87.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.63 -
$2.89
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.5% below Wall St target ($5.25)
Trading Range Analysis
30-Day Trading Range
$2.63 -
$2.89
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.67
Resistance Level
$2.99
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.98
Wall Street Target
$5.25
(+87.5%)
Revenue Growth (YoY)
844.7%
Profit Margin
-240.1%
Share & Embed Analysis
Last updated: May 14, 2026 7:22 PM ET
Data refreshes hourly during market hours. Next update: 8:22 PM
Data refreshes hourly during market hours. Next update: 8:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 51 HOLD |
